TScan Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $10.3M | $2.8M | $21.0M | $13.5M | $10.1M |
| Operating income | -$135.8M | -$134.8M | -$93.5M | -$66.6M | -$48.6M |
| Operating expenses | $146.1M | $137.6M | $114.5M | $80.2M | $58.8M |
| Cash from operations | -$135.3M | -$110.8M | -$61.4M | -$66.5M | -$48.7M |
| Capital expenditure | $4.4M | $3.8M | $3.1M | $4.2M | $9.9M |
| Free cash flow | -$139.7M | -$114.6M | -$64.5M | -$70.7M | -$58.6M |
| Total assets | $228.8M | $371.1M | $272.1M | $199.1M | $188.1M |
| Total liabilities | $105.7M | $130.1M | $121.3M | $99.7M | $27.3M |
| Total debt | $32.5M | $32.5M | $30.0M | $30.0M | — |
Shares outstanding 65.4M · Free float 71.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.